AU2013203903A1 - Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound - Google Patents

Abstract

H:\REC\Interoven\NRPortbl\DCC\REC\5035573_i.doc-I 1/04/2013 Provided is a pharmaceutical composition comprising a 11-deoxy-prostaglandin compound represented by formula (I): R1 -A and a fatty acid ester. By mixing the compound of formula (I) and a fatty acid ester, the compound of formula (I) will be stabilized.

Description

Documentl6-11/04/2013 -1 DESCRIPTION PHARMACEUTICAL COMPOSITION COMPRISING 11-DEOXY-PROSTAGLANDIN COMPOUND AND METHOD FOR STABILIZING THE COMPOUND This application is a divisional of Australian Patent Application No. 2008276840, the entire content of which is incorporated herein by reference. TECHNICAL FIELD The present invention relates to a pharmaceutical composition comprising specific 11-deoxy-prostaglandin compound, method for stabilizing said therapeutically effective 11-deoxy-prostaglandin compound and a soft gelatin capsule formulation comprising the 11-deoxy-prostaglandin compound as an active ingredient. BACKGROUND ART Prostaglandin has a prostanoic acid structure indicated by the formula: k 8 00 (oa chain) (w chain) and there are many prostaglandins expressing a variety of therapeutic effects. 11-deoxy-prostaglandin compounds such as 11-deoxy-15 keto-16,16-difluoro prostaglandin El: 0 are useful for the improvement of central nerves system dysfunction as well as peripheral circular dysfunction WO 2009/011449 PCT/JP2008/063222 2 (WO2006/093348 and W02006/080549, the cited references are herein incorporated by reference). SUMMARY OF THE INVENTION An object of the present invention is to provide 5 a pharmaceutical composition comprising a specific 1I deoxy-prostaglandin compound in a stabilized form. Another object of the present invention is to provide a method for stabilizing the specific l-deoxy-prostaglandin compound. A further object of the present invention is to provide a 10 soft gelatin capsule. In the first aspect of the present invention, a pharmaceutical composition comprising a 11-deoxy prostaglandin compound represented by the formula (I): L RC-A 15 wherein L and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy (lower) alkyl, lower alkanoyloxy or oxo, wherein the five-memnbered ring may optionally have at least one double bond; A .is -CH3, -CH 2 OH, -COCH 2 OH, -COOH or a functional 20 derivative thereof; WO 2009/011449 PCT/JP2008/063222 3 Ri is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon, which is unsubstituted or substituted with halogen, lower alkyl, hydroxy, oxo, aryl or heterocyclic group, and at least one carbon atom in the 5 aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and Ro is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkyl, lower 10 alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, heterocyclic group or hetrocyclic-oxy group; lower alkoxy; lower alkanoyloxy; cyclo (lower) alkyl; cyclo (lower) alkyloxy; aryl; aryloxy; heterocyclic group; heterocyclic-oxy group, and at least 15 one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur, and a fatty acid ester. In the second aspect of the present application, a method for stabilizing the ll-deoxy-prostaglandin 20 compound defined as above, which comprises mixing the 1I deoxy-prostaglandin compound and a fatty acid ester is provided. In the third aspect of the present application, a soft gelatin capsule formulation, which comprises a soft 25 gelatin capsule shell comprising a polyol and/or sugar WO 2009/011449 PCT/JP2008/063222 4 alcohol as a plasticizer, and a pharmaceutical composition comprising the above defined ll-deoxy-prostaglandin compound and a pharmaceutically acceptable vehicle, wherein the composition is incorporated in the gelatin capsule 5 shell. A more preferred ll-deoxy--prostaglandin compound used in the present invention is represented by the formula (II)I: L B-C-Ra 11 z 10 wherein B is single bond, -CH 2

-CH

2 -, -CH=CH-, -C=C-,

CH-CH

2

-CH

2 -, -CH=CH-CH.

2 -, -CH 2 -CIH{=CH-, -C=C-CH 2 - or -CH 2 Z is R4 R5 , R4 R5 or o 15 wherein R 4 and R_ are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy (lower) alkyl, wherein R 4 and Rs are not hydroxy and lower alkoxy at the same time; Ra is a saturated or unsaturated lower or medium WO 2009/011449 PCT/JP2008/063222 5 aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkyl, lower alkoxy, Lower alkanoyloxy, cycle o (lower) alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, heterocyclic group or 5 hetrocyclic-oxy group; lower alkoxy; lower alkanoyloxy; cyclo(lower) alkyl; cyclo(lower) alkyloxy; aryl; aryloxy; heterocyclic group; heterocyclic-oxy group, and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and 10 L, N, A and R 1 are the same as defined above. A group of particularly preferable ll-deoxy prostaglandin compounds among the above-described compounds is represented by the formula (III): L RI-A X1 X2 % (111) B-C-C-R2-R3 11 z 15 wherein Xi and X 2 are hydrogen, lower alkyl, or halogen;

R

2 is a single bond or lower alkylene;

R

3 is lower alkyl, lower alkoxy, lower alkanoyloxy, cyclo (lower ) alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, 20 heterocyclic group or heterocyclic-oxy group, and at least WO 2009/011449 PCT/JP2008/063222 one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and L, A, B, R, and Z are the same as defined above. BEST MODE FOR CARRYING OUT THE INVENTION 5 In the above formula, the term "unsaturated" in the definitions for R 1 and Ra represents an aliphatic hydrocarbon that include one or more double bonds and/or triple bonds that are isolatedly, separately or serially present between carbon atoms of the main and/or side chains. 10 According to the usual nomenclature, an unsaturated bond between two serial positions is represented by denoting the lower number of the two positions, and an unsaturated bond between two distal positions is represented by denoting both of the positions. 15 The term "lower or medium aliphatic hydrocarbon" refers to a straight or branched chain hydrocarbon group having 1 to 14 carbon atoms (for a side chain, 1 to 3 carbon atoms are preferable) and preferably 1 to 10, especially 6 to 10 carbon atoms for R 1 and 1 to 10, 20 especially I to 8 carbon atoms for Ra. The term "halogen" covers fluorine, chlorine, bromine and iodine. The term "lower" throughout the specification is intended to include a group having 1 to 6 carbon atoms 25 unless otherwise specified.

WO 2009/011449 PCT/JP2008/063222 7 The term "lower alkyl" refers to a straight or branched chain saturated hydrocarbon group containing 1 to 6 carbon atoms and includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, 5 pentyl and hexyl. The term "lower alkoxy" refers to a group of lower alkyl-O-, wherein lower alkyl is defined as above. The term "hydroxy(lower)alkyl" refers to a lower alkyl as defined above which is substituted with at least 10 one hydroxy group such as hydroxymethyl, 1-hydroxyethyl, 2 hydroxyethyl and 1-methyl-1-hydroxyethyl. The term "lower alkanoyloxy" refers to a group represented by the formula RCO-O-, wherein RCO- is an acyl group formed by oxidation of a lower alkyl group as defined 15 above, such as acetyl. The term "cyclo (lower) alkyl" refers to a cyclic group formed by cyclization of a lower alkyl group as defined above but contains three or more carbon atoms, and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl 20 and cyclohexyl. The term "cyclo (lower) alkyloxy" refers to the group of cyclo(lower)alkyl-O-, wherein cyclo(lower)alkyl is defined as above. The term "aryl" may include unsubstituted or 25 substituted aromatic hydrocarbon rings (preferably WO 2009/011449 PCT/JP2008/063222 8 monocyclic groups), for example, phenyl, naphthyl, tolyl and xylyl. Examples of the substituents are halogen atom and halogen substituted lower alkyl, wherein halogen atom and lower alkyl are as defined above. 5 The term "aryloxy" refers to a group represented by the formula ArO-, wherein Ar is aryl as defined above. The term "heterocyclic group" may include mono to tri-cyclic, preferably monocyclic heterocyclic group which is 5 to 14, preferably 5 to 10 membered ring having 10 optionally substituted carbon atom and 1 to 4, preferably 1 to 3 of 1 or 2 type of hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom. Examples of the heterocyclic group include furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, 15 pyrazolyl, furazanyl, pyranyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, 2-pyrrolinyl, pyrrolidinyl, 2 imidazolinyl, imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, piperidino, piperazinyl, morpholino, indolyl, benzothienyl, quinolyl, isoquinolyl, purinyl, quinazolinyl, carbazolyl, 20 acridinyl, phenanthridinyl, benzimidazolyl, benzimidazolinyl, benzothiazolyl, phenothiazinyl. Examples of the substituent in this case include halogen, and halogen substituted lower alkyl group, wherein halogen atom and lower alkyl group are as described above. 25 The term "heterocyclic-oxy group" means a group WO 2009/011449 PCT/JP2008/063222 9 represented by the formula HcO-, wherein Hc is a heterocyclic group as described above. The term "functional derivative" of A includes salts (preferably pharmaceutically acceptable salts), 5 ethers, esters and amides. Suitable "pharmaceutically acceptable salts" include conventionally used non-toxic salts, for example a salt with an inorganic base such as an alkali metal salt (such as sodium salt and potassium salt), an alkaline earth 10 metal salt (such as calcium salt and magnesium salt) , an ammonium salt; or a salt with an organic base, for example, an amine salt (such as methylamine salt, dimethylamine salt, cyclohexylamine salt, benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine 15 salt, triethanolamine salt, tris (hydroxymethylamino) ethane salt, monomethyl- monoethanolamine salt, procaine salt and caffeine salt), a basic amino acid salt (such as arginine salt and lysine salt), tetraalkyl ammonium salt and the like. These salts may be prepared by a conventional process, 20 for example from the corresponding acid and base or by salt interchange. Examples of the ethers include alkyl ethers, for example, lower alkyl ethers such as methyl ether, ethyl ether, propyl ether, isopropyl ether, butyl ether, isobutyl 25 ether, sec-butyl ether, t-butyl ether, pentyl ether and 1- WO 2009/011449 PCT/JP2008/063222 10 cyclopropyl ethyl ether; and medium or higher alkyl ethers such as octyl ether, diethylhexyl ether, lauryl ether and cetyl ether; unsaturated ethers such as oleyl ether and linolenyl ether; lower alkenyl ethers such as vinyl ether, 5 allyl ether; lower alkynyl ethers such as ethynyl ether and propynyl ether; hydroxy(lower) alkyl ethers such as hydroxyethyl ether and hydroxyisopropyl ether; lower alkoxy (lower)alkyl ethers such as methoxymethyl ether and 1 methoxyethyl ether; optionally substituted aryl ethers 10 such as phenyl ether, tosyl ether, sec-butyl ether, t butylphenyl ether, salicyl ether, 3, 4-di-methoxyphenyl ether and benzamidophenyl ether; and aryl (lower) alkyl ethers such as benzyl ether, trityl ether and benzhydryl ether. 15 Examples of the esters include aliphatic esters, for example, lower alkyl esters such as methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, sec-butyl ester, t-butyl ester, pentyl ester and 1 cyclopropylethyl ester; lower alkenyl esters such as vinyl 20 ester and allyl ester; lower alkynyl esters such as ethynyl ester and propynyl ester; hydroxy(lower)alkyl ester such as hydroxyethyl ester; lower alkoxy (lower) alkyl esters such as methoxymethyl ester and 1-methoxyethyl ester; and optionally substituted aryl esters such as, for example, 25 phenyl ester, tosyl ester, t-butylphenyl ester, salicyl WO 2009/011449 PCT/JP2008/063222 ester, 3,4-di-methoxyphenyl ester and benzamidophenyl ester; and aryl (lower) alkyl ester such as benzyl ester, trityl ester and benzhydryl ester. The amide of A mean a group represented by the 5 formula -CONR'R", wherein each of R' and R" is hydrogen atom, lower alkyl, aryl, alkyl- or aryl-Sulfonyl, lower alkenyl and lower alkynyl, and include for example lower alkyl amides such as methylamide, ethylamide, dimethylamide and diethylamide; arylamides such as anilide and toluidide; 10 and alkyl- or aryl-sulfonylamides such as methylsulfonylamide, ethylsulfonyl-amide and tolylsulfonylamide. Preferred examples of L include hydroxy and oxo which provide a 5-membered ring structure of, so called, 15 especially PGF or PGE type. Preferred examples of A are -COOH, its pharmaceutically acceptable salt, ester and amide thereof. Preferred example of B is -CH 2

-CH

2 -, which provide the structure of so-called, 13, 14--dihydro type 20 compound. Preferred example of Xi and X 2 is hydrogen, or that at least one of them is halogen, more preferably, both of them are halogen, especially, fluorine that provides a structure of, so called 16,16-difluoro type compound. 25 Preferred R1 is a hydrocarbon containing 1-10 WO 2009/011{449 PCT/JP2008/063222 12 carbon atoms, preferably, 6-8 carbon atoms. Further, at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen., nitrogen or- sulfur. Examples of R.1 include, for example, th e 5 following groups: -0H 2

-CH

2

-CH

2

-H

2 -Ci 2

-CH

2 -,

-CI{--CH-CH-CH

2

-CII

2

-CIH

2 - ,

-CH

2

-CH

2

-CH

2

-CI

2 -- CH=CH-,

-H

2 0 CC-CH?-CH 2

-CH

2 -, 10 -CH 2

-

2

-CI-

2

-CH

2 -CH (CH 3 ) -CH 2 --, 0 2 -C H 2

--C'H

2 C 2 -O-CH1 2 ---, -hU-CH=CH-0H-OCH

%--

2 - C:-C -CH 2 -0- CH 2 -,

-CH

2 - CH 2 -- CH -CH 2

-C

C

H2 H 2 t-, 15-CH )-CH=C'-H-CH-" 2

-CH

2 -CH.4 2

-CII

2 -,

-CH

2

-C

H

2CH-CH 2

?-CH

2

-CHC

-CH

2 -CE CC.-'CHCH 2

-CH

2 -,

-CH

2 -CH-CH -H 2

-CH

2 -C'j(CH 3 ) -CH -,

-CH

2

-CH

2 -CH19-CH 2 1--H 2

CH

2

-CH

2

-CH

2 -, 20 -CH 2 --CH=CH-Cr'H 2

-C'-

2 CH2-CH 2 -CHi 2 -, .-- CH 2

-CH

2

-CH

2

-%-CH

2

-CH-CH

2 -CHCH--,

-CH

2

-C=-C-C-

2

-CKT'

2

-CI

2 -- CH 2

-C-H

2 -, and

-CH

2 -CH2-CH 2

-CH

2 -- H 2

-CH-

2 -CI -C 3 )1 11 2 Preferred Ra is a hydrocarbon containing 1--10 25 carbon atoms, more preferably 1-8 carbon atoms and WO 2009/011449 PCT/JP2008/063222 13 especially 5-7 carbon atoms. The hydrocarbon of Ra may additionally have one or two side chains each having one carbon atom. Preferred R 2 is single bond. 5 Preferred R 3 is lower alkyl and more preferably, alkyl having 4-6 carbon atoms. The lower alkyl of R 3 may additionally have one or two side chains each having one carbon atom. The typical examples of the present compounds are 10 11-deoxy-13,14-dihydro-l6,16-difluoro-PGE or PGF compound, 11-deoxy-13, 14-dihydro-15-keto-16, 16-difluoro-PGE or PGF compound, 2-decarboxy-2- (2-carboxyethyl) -11--deoxy-13, 14 dihydro-15-keto-16,16-difluoro-PGE or PGF compound, or 11 deoxy-13,14-dihydro-15-keto-16, 16-difluoro-20-ethyl-PGE or 15 PGF compound and its derivative or analogue. The preferred examples of the compounds may include ll-deoxy-13,14-diihydro-15-keto-16,16-difluoro-PGEi, ll-deoxy-13, 14-dihydro-16, 16-di fluoro-PGEi, 11-deoxy-13,14 dihydro-1 5-keto-16,16-difluoro--PGEi isopropyl ester, 2 20 decarboxy-2- (2-carboxyethyl) -l1-deoxy-1 3, 14-dihydro-15 keto-16,l6-difluoro-PGEi isopropyl ester, 2-decarboxy-2-(2carboxvethyl) -l-deoxy-13, 14--dihydro-15-keto-16, 16 dif luoro -PGEI, 11-deoxy-13, 14-dihydro-15-ket o-16, 16 difluoro-20-methy-PGEi isopropyl ester, 1-deoxy-13,14 25 di hydro-15-keto--16, 16-difluoro-20-methyl-PGEI, 11-deoxy- WO 2009/011449 PCT/JP2008/063222 14 13, 14-dihydro-15-keto-16, 16-difluoro-20-ethyl-PGEi, 11 deoxy-13,14-dihydro-15-keto-16,16-difluoro-PGE 1 methyl ester, ll-deoxy-13, 14-dihydro-15-keto-16, 16-difluoro-20 ethyl-PGEI isopropyl ester or ll-deoxy-13,14-dihydro-15 5 keto-16,16-difluoro-20-ethyl-PGFia isopropyl ester. In the present invention, the l-deoxy prostaglandin compound of formula (I) covers any isomers of formula (I) including the individual tautomeric isomers, the mixture thereof, or optical isomers, the mixture 10 thereof, a racemic mixture, and other steric isomers. Some of the compounds used in the present invention may be prepared by the method disclosed in W02006/080549 and W02006/093348 and the references cited therein (these cited references are herein incorporated by 15 reference). The pharmaceutical composition of the present invention comprises the above described ll-deoxy prostaglandin compound and a fatty acid ester. Examples of the fatty acid esters used in the 20 present invention may include fatty acid esters obtained from a fatty acid and an alcohol, for example, saturated or unsaturated glycerides which may have a branched chain. Preferred fatty acid esters may include a medium or higher chain fatty acid having at least C6, preferably C6-24 25 carbon atoms, for example caproic acid (C6), caprylic WO 2009/011449 PCT/JP2008/063222 15 acid(C8), capric acid(CIO), lauric acid(C12), myristic acid (014), palmitic acid(C16), palmitoleic acid(C16), stearic acid(C18), oleic acid (C18), linoleic acid(C18), linolenic acid(C18), ricinolic acid(C18) and arachic acid(C20). 5 Preferred alcohols which consists the fatty acid ester may comprise CI-6 monovalent alcohol and polyols such as glycerine, polyethyleneglycol and propyleneglycol. Preferred fatty acid esters may include a glyceride of a saturated or unsaturated fatty acid which 10 may have a branched chain, a glycerine fatty acid ester and a propyleneglycol fatty acid ester. Two or more glycerides may be used as a mixture. Examples of the mixture of glycerides are mixture of caprylic acid triglyceride and capric acid triglyceride, vegetable oils such as castor oil, corn oil, olive oil, sesame oil, rape oil, salad oil, cottonseed oil, camellia oil, peanut oil, palm oil and sunflower oil. A fatty acid ester derived from a fatty acid and a monovalent alcohol is also preferably used. The fatty 20 acid ester may preferably be an ester of a C8-20 fatty acid and a C2-3 monovalent alcohol, such as isopropyl miristate, isopropyl palmitate, ethyl linoleate and ethyl oleate. The composition of the present invention may be prepared by dissolving or dispersing the above described 25 11--deoxy -prostaglandin compound in the fatty acid ester.

WO 2009/011449 PCT/JP2008/063222 16 When it is difficult to dissolve the 11-deoxy-prostaglandin compound directly in the fatty acid ester, each of them may be dissolved in a solvent in which both of them are soluble respectively, and then the solutions may be combined. 5 The amount of the fatty acid ester in the composition relative to the amount of the 11-deoxy prostaglandin compound is not limited as long as the 11 deoxy-prostaglandin compound is stable in the composition. In general, the amount of the fatty acid ester per one part 10 of the 11-deoxy-prostaglandin compound may be 1-5,000,000, preferably, 5-1,000,000 and most preferably, 10-500,000 parts by weight. The pharmaceutical composition of the present invention may further comprise physiologically acceptable 15 additives which do not provide adverse effect to the stability of the compound of formula (I) The additives which may be employed in the present invention include, but not limited to, excipients, diluents, fillers, solvents, lubricants, adjuvants, binders, disintegrants, coatings, 20 capuslating agents, ointment bases, suppository bases, aerozoles, emulsifiers, dispersing agents, suspensions, viscosity increasing agents, isotonic agents, buffers, analgesic agents, preservatives, anti-oxidants, corrigents, flavors, colorants, and functional agents such as 25 cyclodextrin, biologically degradable polymers. The WO 2009/011449 PCT/JP2008/063222 17 additives may be selected from those described in any of general textbooks in the pharmaceutical field. The composition of the present invention may further comprise one or more other pharmaceutically active ingredient. 5 According to the present invention, the dosage form of the composition is not specifically limited and is preferably in the form suitable for oral administration. More preferably, the composition of the present invention is in the form of capsule such as hard capsule or soft 10 capsule. Sugar alcohol solution derived from corn starch and glycerine have been known that they can be used as plasticizer for manufacturing soft-gelatin capsules. Sugar alcohol solution derived from corn starch and glycerine 15 have also been known to deteriorate the stability of 11 deoxy-prostaglandin compound recited in the instant application when admixed directly with the compound and therefore, the art would expect that sugar alcohols or polyols are not useful as plasticizer for manufacturing 20 soft gelatin capsule to incorporate the l1---deoxy prostaglandin compound of the invention as an active ingredient. The inventor have surprisingly found that soft gelatin capsule shell manufactured from gelatin and a sugar alcohol or a polyol as a plasticizer will not deteriorate 25 the stability of il-deoxy-prostaglandin compound of the WO 2009/011449 PCT/JP2008/063222 18 invention when the composition compising the 11-deoxy prostaglandin compound and a fatty acid ester is incorporated in the soft gelatin capsule shell. According to the present invention, the 5 composition which is filled in the soft-gelatin capsule shell may be obtained by dissolving or dispersing the above-described 11-deoxy-prostaglandin. compound in a pharmaceutically acceptable vehicle which is liquid at the room temperature. When it is difficult to dissolve the 11 10 deoxy-prostaglandin compound directly in the vehicle, each of them may be dissolved in a solvent in which both of them are soluble respectively, and then the solutions may be combined. The pharmaceutically acceptable vehicle may be 15 any of those employed for the manufacture of medicaments as long as they do not deteriorate the stability of the active ingredient, 11-deoxy-prostaglandin compound. Preferred embodiment of the composition to be filled in the soft gelatin capsule shell is a composition 20 comprising the 11-deoxy-prostaglandin compound and a fatty acid ester. The amount of the vehicle in the composition relative to the amount of the 11-deoxy-prostagiandin compound is not limited as long as the 11-deoxy 25 prostaglandin compound is stable in the final formulation.

WO 2009/011449 PCT/JP2008/063222 19 In general, the amount of the vehicle per one part of the l-deoxy-prostaglandin compound may be 1-5, 000, 000, preferably, 5-1,000,000 and most preferably, 10-500,000 parts by weight. 5 According to the present invention, the pharmaceutical composition to be filled in the soft gelatin capsule may further comprise oil solvent other than the fatty acid ester such as mineral oil, liquid paraffin, and tocopherol. 10 Polyols used in the present invention are alcohols having two or three hydroxy groups. Preferred examples of polyols may include glycerine, polyethyleneglycol and propyleneglycol. Sugar alcohol plasticizer used in the present 15 invention is an alcohol obtained by hydrogen reduction of the aldehyde group of a saccharide. Examples may comprise sorbitol, mannitol, maltitol, lactitol, palatinit, xylitol and erithyritol; and sugar alcohol solution derived from corn starch, i.e. a mixture of sorbitol, sorbitan, mannitol 20 and hydrogenated starch hydrolysate, hydrogenated maltose starch syrup, i.e. a mixture of maltitol, sorbitol and oligosaccharide alcohol. Preferred sugar alcohols may include sorbitol, sorbitan, maltitol, sugar alcohol solution derived from 25 corn starch and hydrogenated maltose starch syrup.

WO 2009/011449 PCT/JP2008/063222 20 Especially, sugar alcohol solution derived from corn starch and available on market under the name "Anidrisorb" or "Polysorb" is preferably used. According to the invention, the amount of the 5 sugar alcohol used for preparing the shell of the soft gelatin capsule is not specifically limited as long as the physical properties of the resulting capsule is not deteriorated. In general, the amount of sugar alcohol plasticizer is 20-60 parts by weight, preferably, 30-50 10 parts by weight per 100 parts by weight of gelatin. The soft gelatin capsule formulation comprising the ll-deoxy-prostaglandin compound as an active ingredient may be manufactured by filling a composition comprising the ll-deoxy-prostaglandin compound and a pharmaceutically 15 acceptable vehicle in soft gelatin capsule shell manufactured from gelatin and a plasticizer, polyol and/or sugar alcohol. Thus obtained soft gelatin capsule formulation can keep the ll-deoxy-prostaglandin compound stably for long term. Manufacture of soft gelatin capsule 20 shell as well as filling the composition into the shell may be conducted according to a conventional manner. The present invention will be explained in more detail by means of the following examples, which are illustrated by way of example only and never intended to 25 limit the scope of the present invention.

WO 2009/011449 PCT/JP2008/063222 21 EXAMPLE 1 Compound 1: 11-deoxy-13, 14-dihydro-15-keto-16, 16 difluoro PGEl 5 Compound 1 was dissolved in a vehicle shown in table 1 below to give 250pg/g solution. Then, the solution was put in a hard grass container and heated at 55'C. The precise amount of Compound 1 in the solution was determined by means of HPLC (day 0). The container was kept at 55 0 C 10 for 10 days and after that the precise amount of the compound 1 was determined by means of HPLC (day 10). The determination of the amount of the compound was carried out as follows. About 0.2g of the sample was mixed with exactly 2mL of internal standard solution and 15 then with a dissolving agent shown in Table 1 to give 5mL of sample solution. About 5mg of the reference standard compound 1 was weighted precisely and added with acetonitrile to give exactly SmL solution. Exactly lml of the solution was obtained and added with exactly 4mL of the 20 internal standard solution, and then added with the dissolving agent to give 1OmL of reference solution. The fluorescent labeling agent was added to the respective solution, stirred and stood at room temperature for more than 30 minutes. After that, 2% acetic acid in 25 acetonitrile was added to the solution, stirred and reacted WO 2009/011449 PCT/JP2008/063222 22 at room temperature for more 30minutes to give the sample and standard solutions. Then, the respective solution in an amount that theoretically gives 3.6ng of compound 1 was loaded on the column and analyzed under the condition as 5 follows: HPLC analysis condition: Column: 5mm X 25cm stainless steel column packed with octadecylsilane treated silica gel for HPLC (5pm) Mobile phase: mixture of acetonitrile (HPLC grade) and 10 perchlorate buffer Temperature: 35 0 C Detector: spectrophotofluorometer Results are shown in Table 1 15 Table 1 Stability of Compound 1: stored at 55*C vehicle dissolving day 01 aay I 1 _agent 1 medium chain fatty acetonitrile 94.1 97.0% acid triglyceride 2 corn oil ethyl 93.1% 94.8% 3 soy oil acetonitrile 98.2% 94.6% 4 glycerine fatty acid acetonitrile ester 3 93.3% 96.4 5 propyleneglycol fatty acetonitrile acid ester ' s isopropyl pa imitate acetonitrie |93.9% 96.7% 1) percentage based on the theoretical amount (250pg/g) 2) Miglyol 812N, constituting fatty acids: caproic acid WO 2009/011449 PCT/JP2008/063222 23 (C6) NMT 2.0%, caprylic acid (C8) 50.0-80.0%, capric acid (C10) 20.0-50.0%, lauric acid (C12 NMT) 3.0%, and myristic acid (C14) NMT 1.0% (NF/EP). 3) Inwitor 742, total monoglycerides are 44-55% 5 4) Rikemal PO-10OV, proplylene glycol monooleate, Riken Vitamin Co., Ltd. COMPARATIVE EXAMPLE 1 According to the same manner as described in 10 Example 1, stability of the compound 1 in various vehicles was measured. Results are shown in Table 2. Table 2 15 Stability of Compound 1: stored at 55 'C vehicle dissolving dy ) day day 10i __ __ __ _ __ __ _ agent __ _ _ 1u0 1 (compound 1 only) acetonitrile 95.4% 8238% 2 concentrated glycerin methanol 20.9% 20.0% 3 hydrogenated maltose acetonitrile/ . 3 starch syrup water(1:1) 4 sugar alcohol solution methanol 3.8% 5.6% derived from corn starch 5 Macrogol 400 acetonitrile 92.2% 80.7% (polyethyleneglycol) 6 polysorbate 80 acetonitrile 92.1% 64.5% 7 oleic acid methanol 61.9% 51.6% 1) percentage based on the theoretical amount (250pg/g) According to the results of Example 1 and Comparative Example 1, the stability of compound 1 was WO 2009/011449 PCT/JP2008/063222 24 significantly improved by admixing the same with a fatty acid ester such as glyceride. in contrast, the stability of the compound 1 was poor in polyol such as glycerine, sugar, sugar alcohol, polyethylene glycol, polysorbate 80, 5 and fatty acid. Preparation Example (Soft gelatin capsule) Compound 1: 11-deoxy-13, 14-dihydro-15-keto-16, 16 difluoro PGE1 was used. 10 Formulation Example Sugar alcohol solution derived from corn starch 60 parts by weight was added in an appropriate amount of water, stirred and heated. Then, gelatin 100 parts by weight was added thereto to give gelatin solution. 15 Compound I was dissolved in medium chain fatty acid triglyceride (USP/NF grade) to give a liquid mixture containing 120ug/g of compound 1. The gelatin solution and the liquid mixture were loaded on a soft capsule forming and filling machine to give capsule containing the liquid 20 mixture, and dried to give soft gelatin capsule with an appropriate hardness. Example 2 The soft gelatin capsules obtained in the 25 formulation example were kept at 40'C for 6 months or at WO 2009/011449 PCT/JP2008/063222 25 55*C for one month. After that, 20 capsules were swelled with purified water and ethyl acetate (HPLC grade) lOmL was added thereto. The capsule was then cut opened and the liquid contained therein was obtained. 1mL of the internal 5 standard solution per 100pg of theoretical amount of compound I was added to the liquid, and ethyl acetate (HPLC grade) was added so that the theoretical concentration of compound 1 was 10pg/mL to give a sample solution. On the other hand, about 0.025g of standard 10 Compound I was precisely weighted and added with ethyl acetate (HPLC grade) to give exactly 100mL solution. 2mL of the solution was measured, exactly 5mL of the internal standard solution was added thereto and ethyl acetate (HPLC grade) was added so that the total amount was 50mL to give 15 the standard compound I solution. The fluorescent labeling agent was added to the sample and standard solutions, stirred and reacted at room temperature. The respective solution in an amount that 20 theoretically gives 3.6ng of compound 1 was loaded on the column and analyzed under the condition as follows: HPLC analysis condition: column: 5mm X 25cm stainless steel column packed with octadecylsilane treated silica gel for HPLC (5pm) 25 Mobile phase: mixture of acetonitrile HPLC grade: WO 2009/011449 PCT/JP2008/063222 26 methanol HPLC grade: ammonium acetate (0.05mol/L) Temperature: 35 0 C Detector: spectrophotofluorometer The amount of the compound 1 in the sample solution was 5 determined by using a one point calibration curve. Results are shown in Tables 3 and 4 below: Table 3 Stability of Compound 1: stored at 40"C amounts of compound 1 gelatin solution on 1, 3 and 6 months _ (% vs day 0) gelatin sugar alcohol Initial 1mo 3mo 6mo solution 100 60 100 99.8 98.0 98.8 10 Table 4 Stability of Compound 1: stored at 550C amounts of compound 1 gelatin solution on 1, 2 and 4 weeks (% vs day 0) gelatin sugar Alcohol Initial 1w 2w 4w s o. . n lu t i o n ----- -- -- ----- ---------------- 100 60 100 100.2 100.1 99.5 The sugar alcohol solution/polyol which decreased the stability of compound I when directly admixed with the 15 compound will not affect the stability when used as plasticizer.

Docun tl6-ll/04/2013 -26A Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Claims (9)

1. A soft gelatin capsule formulation, which comprises: a soft gelatin capsule shell comprising a polyol and/or sugar alcohol as a plasticizer, and a pharmaceutical composition comprising a 11-deoxy prostaglandin compound represented by formula (I): L R 1 -A N Ro (I) wherein L and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy(lower)alkyl, lower alkanoyloxy or oxo, wherein the five-membered ring may optionally have at least one double bond; A is -CH 3 , -CH 2 OH, -COCH 2 OH, -COOH or a functional derivative thereof; R 1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon, which is unsubstituted or substituted with halogen, lower alkyl, hydroxy, oxo, aryl or heterocyclic group, and at least one of carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and Ro is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkyl, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group or hetrocyclic-oxy group; lower alkoxy; lower alkanoyloxy; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; aryloxy; heterocyclic group; heterocyclic-oxy group, and at least one of carbon atom in Document 6-l1/04/20l3 -28 the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur, and a pharmaceutically acceptable vehicle, wherein said pharmaceutical composition is incorporated in the soft gelatin capsule shell.

2. The soft gelatin capsule formulation as described in Claim 1, wherein said 11-deoxy-prostaglandin compound is a

11-deoxy-13,14-dihydro-prostaglandin compound. 3. The soft gelatin capsule formulation as described in Claim 1, wherein said 11-deoxy-prostaglandin compound is a 11-deoxy-15-keto-prostaglandin compound. 4. The soft gelatin capsule formulation as described in Claim 1, wherein said 11-deoxy-prostaglandin compound is a 11-deoxy-13,14-dihydro-15-keto-prostaglandin compound. 5. The soft gelatin capsule formulation as described in Claim 1, wherein said 11-deoxy-prostaglandin compound is a 11-deoxy-16-mono or dihalogen-prostaglandin compound. 6. The soft gelatin capsule formulation as described in Claim 1, wherein said 11-deoxy-prostaglandin compound is a 11-deoxy-13,14-dihydro-16-mono or dihalogen-prostaglandin compound. 7. The soft gelatin capsule formulation as described in Claim 1, wherein said 11-deoxy-prostaglandin compound is a 11-deoxy-15-keto-16-mono or dihalogen-prostaglandin compound. Document 6-l1/04/20l3 -29 8. The soft gelatin capsule formulation as described in Claim 1, wherein said 11-deoxy-prostaglandin compound is a 11-deoxy-13,14-dihydro-15-keto-16-mono or dihalogen prostaglandin compound. 9. The soft gelatin capsule formulation as described in Claim 1, wherein said 11-deoxy-prostaglandin compound is a 11-deoxy-13,14-dihydro-15-keto-16-mono or difluoro prostaglandin compound. 10. The soft gelatin capsule formulation as described in Claim 1, wherein said 11-deoxy-prostaglandin compound is a 11-deoxy-13,14-dihydro-15-keto-16-mono or dihalogen prostaglandin E or F compound. 11. The soft gelatin capsule formulation as described in Claim 1, wherein said 11-deoxy-prostaglandin compound is a 11-deoxy-13,14-dihydro-15-keto-16-mono or difluoro prostaglandin E or F compound.

12. The soft gelatin capsule formulation as described in Claim 1, wherein said prostaglandin compound is 11-deoxy 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin El compound.

13. The soft gelatin capsule formulation as described in Claim 1, wherein said pharmaceutically acceptable vehicle is a fatty acid ester.

14. The soft gelatin capsule formulation as described in Claim 13, wherein said fatty acid ester is a glyceride. Document 6-l1/04/20l3 -30

15. The soft gelatin capsule formulation as described in Claim 13, wherein said polyol is glycerine.

16. The soft gelatin capsule formulation as described in Claim 1, wherein said sugar alcohol is selected from the group consisting of sorbitol, sorbitan, maltitol, sugar alcohol solution derived from corn starch, hydrogenated maltose starch syrup and a mixture thereof.

17. The soft gelatin capsule formulation as described in Claim 16, wherein said sugar alcohol is mainly consisting of sorbitol and sorbitan.